JP2024531507A5 - - Google Patents
Info
- Publication number
- JP2024531507A5 JP2024531507A5 JP2024513347A JP2024513347A JP2024531507A5 JP 2024531507 A5 JP2024531507 A5 JP 2024531507A5 JP 2024513347 A JP2024513347 A JP 2024513347A JP 2024513347 A JP2024513347 A JP 2024513347A JP 2024531507 A5 JP2024531507 A5 JP 2024531507A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239304P | 2021-08-31 | 2021-08-31 | |
| US63/239,304 | 2021-08-31 | ||
| PCT/US2022/075610 WO2023034761A1 (en) | 2021-08-31 | 2022-08-29 | Treatment of liver diseases with camp responsive element binding protein 3 like 3 (creb3l3) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531507A JP2024531507A (ja) | 2024-08-29 |
| JPWO2023034761A5 JPWO2023034761A5 (https=) | 2025-06-09 |
| JP2024531507A5 true JP2024531507A5 (https=) | 2025-06-09 |
Family
ID=83457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513347A Pending JP2024531507A (ja) | 2021-08-31 | 2022-08-29 | Ｃａｍｐ応答性エレメント結合タンパク質３様３（ｃｒｅｂ３ｌ３）阻害剤による肝疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230160012A1 (https=) |
| EP (1) | EP4395888A1 (https=) |
| JP (1) | JP2024531507A (https=) |
| KR (1) | KR20240058125A (https=) |
| CN (1) | CN118265529A (https=) |
| AU (1) | AU2022339755A1 (https=) |
| CA (1) | CA3228930A1 (https=) |
| IL (1) | IL310697A (https=) |
| WO (1) | WO2023034761A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR067446A1 (es) * | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
| WO2012051301A1 (en) * | 2010-10-12 | 2012-04-19 | President And Fellows Of Harvard College | Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism |
| EP3220911B1 (en) * | 2014-11-17 | 2018-11-07 | Universitá Degli Studi Salerno | Levosimendan for use as a liver protector |
-
2022
- 2022-08-29 JP JP2024513347A patent/JP2024531507A/ja active Pending
- 2022-08-29 US US17/823,057 patent/US20230160012A1/en active Pending
- 2022-08-29 CA CA3228930A patent/CA3228930A1/en active Pending
- 2022-08-29 IL IL310697A patent/IL310697A/en unknown
- 2022-08-29 AU AU2022339755A patent/AU2022339755A1/en active Pending
- 2022-08-29 CN CN202280067542.3A patent/CN118265529A/zh active Pending
- 2022-08-29 KR KR1020247010325A patent/KR20240058125A/ko active Pending
- 2022-08-29 EP EP22777885.9A patent/EP4395888A1/en active Pending
- 2022-08-29 WO PCT/US2022/075610 patent/WO2023034761A1/en not_active Ceased